阿托伐他汀对急性冠脉综合征患者hs-CRP和IL-6的影响

目的探讨阿托伐他汀对急性冠脉综合征（ACS）患者高敏C反应蛋白（hs-CRP）和白细胞介素-6（IL-6）的影响。方法 86例ACS患者随机分为2组,治疗组（46例）予常规药物治疗＋阿托伐他汀20 mg/d,对照组（40例）仅予以常规治疗,随访1个月。在入选时及观察结束后检测丙氨酸转氨酶（ALT）、天冬氨酸转氨酶（AST）、肌酸激酶（CK）、hs-CRP及IL-6。结果经1个月治疗后,两组患者治疗前后AST、ALT、CK差异无统计学意义（P〉0.05）;对照组hs-CRP及IL-6较治疗前有所降低（P〈0.05）;治疗组hs-CRP及IL-6较治疗前显著降低（P〈0.01）;与对照组比较,治疗后治疗组hs-CRP及IL-6均有所降低（P〈0.01）。结论阿托伐他汀可以降低ACS患者hs-CRP及IL-6水平,抑制冠状动脉粥样斑块的炎症反应。

Effects of Atorvastatin on hs-CRP and IL-6 in patients with acute coronary syndrome

Objective To investigate the effects of Atorvastatin on hs-CRP and IL-6 in acute coronary syndrome. Methods 86 patients with ACS were divided randomly into statin group （n=46） and control group （n=40）. Statin group received Atorvastatin （20rag/d） on the basis of conventional treatment of control group. The levers ofAST, ALT, CK, hs-CRP and IL-6 were detected before and after for 1 treatment months. Results There were no significant differences in the levels ofAST, ALT, and CK between the two groups before and after treatment （P〉0.05）. After treatment the levels of hs-CRP and IL-6 in control group were significantly lower than that before treatment（P〈0.05）. After treatment the levels of hs-CRP and IL-6 in statin group were significantly lower than that of control and before treatment（P〈0.01 and P〈0.001）. Conclusion Atorvastatin can decrease hs-CRP and IL-6 levels in patients with ACS, which contributes to suppression of inflammation response.